Vertex Pharmaceuticals reported mixed Q1 2026 results, posting a revenue of $2.99 billion, slightly below expectations despite a year-over-year increase. The company's strong earnings were buoyed by successful cystic fibrosis therapies and promising new drug sales, even as it announced plans for a 9% workforce reduction to streamline operations. With ambitions to launch new treatments and develop a telehealth platform, Vertex remains focused on innovation in pain management and expanding into autoimmune care.
“Vertex Pharmaceuticals · is expanding · its drug portfolio · actively with new submissions and strong performance in recent earnings”
“Vertex Pharmaceuticals · focuses on · innovative treatments · for pain management and chronic kidney disease”
“Vertex Pharmaceuticals · was founded in · 1989”
“Vertex Pharmaceuticals · is headquartered in · Boston, Massachusetts”
“Vertex Pharmaceuticals · offers · transformative medicines · for people with serious diseases”
“Vertex Pharmaceuticals, Inc. · is · a global biotechnology company”
“Vertex Pharmaceuticals, Inc. · focuses on · development and commercializing therapies for the treatment of cystic fibrosis”
“Vertex Pharmaceuticals, Inc. · focuses on · therapies for infectious diseases”
“Vertex Pharmaceuticals, Inc. · focuses on · therapies for autoimmune diseases”
“Vertex Pharmaceuticals, Inc. · focuses on · therapies for cancer”
“Vertex Pharmaceuticals, Inc. · focuses on · therapies for inflammatory bowel disease”
“Vertex Pharmaceuticals, Inc. · focuses on · therapies for neurological disorders”
